Latest news with #FundIII
Yahoo
4 days ago
- Business
- Yahoo
Quadria Capital closes Fund III fundraising round to advance healthcare at $1.07bn
Singapore-based private equity company Quadria Capital has closed its Fund III fundraising round, which aimed to raise capital to "transform" healthcare across Asia. The fundraising round has secured a total of $1.07bn in commitments and surpassed its original goal of $800m. It is 60% larger than the company's previous fund, which was held in 2020 and raised $600m. The oversubscribed Fund III includes more than $954m in primary commitments and $114m in committed co-investment capital. The total capital pledged is forecast to approach approximately $1.3bn once fully allocated, anticipating a further $300m in co-investment potential during the investment period. Quadria Capital co-founder and managing partner Abrar Mir said: 'Fund III's close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission. 'It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand.' Quadria Capital has received support from its largest existing backers, which include North American and European sovereign wealth funds, strategic corporates and asset managers. The fund has additionally received pledges from institutional backers and support from the Gulf Cooperation Council (GCC) nations, including Saudi Arabia, the United Arab Emirates and Bahrain. Indian investors, including banks, insurance companies and family offices, have also shown interest and contributed capital. Quadria Capital said the fundraising round positions it for structural growth in Vietnam, where the healthcare market is currently worth $25bn. The company claims its investment in FV Hospital, one of the country's largest healthcare providers, has led to "major clinical improvements and substantial enhancements in patient outcomes". Last year, Quadria Capital was in advanced discussions to acquire a minority stake in NephroPlus, an India-based dialysis chain, for around Rs20bn ($250m). "Quadria Capital closes Fund III fundraising round to advance healthcare at $1.07bn" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
New Indian Express
4 days ago
- Business
- New Indian Express
Quadria's oversubscribed fund: What it signals for Asia's healthcare industry
'It reflects the strong global investor confidence in the transformational opportunity within Asian healthcare, where social impact and financial performance go hand in hand,' confirms Abrar Mir, co-founder and managing partner at Quadria Capital. Quadria Capital said in a statement on Tuesday that Fund III drew support from prominent sovereign wealth funds, asset managers, and strategic corporates across North America and Europe. It also secured new commitments from globally recognised institutional investors, with notable participation from leading institutions in the GCC—including Saudi Arabia, the UAE, and Bahrain. In India, the Fund attracted new capital from major banks, insurance companies, and family offices. Additionally, robust re-up commitments from impact investors reaffirm Quadria's dedication to building scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia. Asian Healthcare Scenario Currently Asia's healthcare market is estimated to be $5 trillion, and the healthcare industry is reportedly at a pivotal inflection point and will remain a focal area into 2025. "In India, particularly, we're seeing significant investment interest in single-specialty hospitals, diagnostics, medical devices, and pharmaceutical manufacturing—including active pharma ingredients (APIs) and contract (drug) development and manufacturing (CDM). These segments are poised for growth due to increasing healthcare consumption, cost-efficiency initiatives, and deeper technology integration," says Dr Amit Verma, co-founder and managing partner, Quadria Capital. Healthcare growth funds like Quadria's typically provide the industry with strategic guidance and operational support to help scale their businesses and achieve market leadership. Quadria claims that nearly 40% of Fund III is already deployed. Its current investments include Aragen Life Sciences (a global CRDMO serving 400+ pharmaceutical clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's leading eye care chain). Two new investments in Southeast Asia are expected shortly, it says. India Impact India is rapidly emerging as a strategic hub for global pharmaceutical and MedTech manufacturing as supply chains diversify, especially with the China plus strategy. While the per capita healthcare spending in India remains low at just $74—far below regional peers like Thailand (US$364) and Malaysia (US$487)—with nearly 50% of healthcare costs still paid out-of-pocket, the healthcare focused funds can catalyse Indian healthcare innovation by strategically investing in high-growth areas such as specialised care and pharmaceutical manufacturing, aiming to create scalable, affordable healthcare solutions for over a billion people.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Quadria closes $1.07 bn healthcare fund, seeks growth in India and S Asia
Quadria Capital has closed its Fund III at $1.07 billion after exceeding the target to raise $800 million, said the healthcare-focused private equity (PE) firm on Tuesday. The amount raised includes $954 million in primary commitments and $114 million as co-investment capital. A further $300 million is expected to be raised in co-investments later and the total capital available could reach up to $1.3 billion, said the Singapore-based firm in a statement. The amount raised is almost 60 per cent more from the $600 million the company's second plan got in 2020, making III the largest dedicated healthcare PE fund for South and Southeast Asia. 'Asia's healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single speciality hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing,' said Amit Varma, cofounder and managing partner at Quadria Capital. The sector will grow because of higher healthcare consumption, 'cost-efficiency initiatives and technology integration', he said. Fund III drew participation from existing investors, who boosted their commitments by an average of 80 per cent, as well as global institutions across North America, Europe, the Middle East, and Asia. New backers included sovereign wealth funds, insurance firms, and family offices, particularly from west Asia and India. Fund III is already nearly 40 per cent deployed, with investments in Aragen Life Sciences, NephroPlus, and Maxivision. Two additional transactions in Southeast Asia are expected to close soon, the company said. Founded in 2012, Quadria manages more than $4 billion in assets across 27 companies. The firm said it plans to build a portfolio of about 10 market-leading healthcare businesses with Fund III, through majority and minority stakes, and co-investments.
Business Upturn
5 days ago
- Business
- Business Upturn
Quadria Capital Closes Oversubscribed US$1 Billion Fund III to Advance Healthcare Transformation Across Asia
New Delhi, Delhi, India: Fund close exceeds initial target despite a challenging fundraising environment, reflecting strong investor confidence in India and Southeast Asia healthcare Existing investors increased commitment amount by an average of 80% New capital raised from blue-chip global institutions, alongside a significant rise in Asian investor participation Quadria Capital, Asia's premier healthcare-focused private equity firm, today announced the final close of its Fund III with US$1.07 billion in total commitments, significantly exceeding its original $800 million target. The oversubscribed fundraise comprises over US$954 million in primary commitments and US$114 million in committed co-investment capital. An additional US$300 million co-investment capacity is anticipated over the course of the investment phase, bringing total committed capital to approximately US$1.3 billion upon full deployment. This latest fundraise is around 60% larger than the firm's previous $600m fund raised in 2020, cementing Quadria's position as the largest dedicated healthcare private equity fund in South and Southeast Asia. 'Fund III's close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission,' said Abrar Mir, Co-Founder and Managing Partner, Quadria Capital. 'It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand.' Global Institutional Backing Across Continents At a time when global capital is cautious, Quadria's ability to consistently attract top-tier global investors underscores the strong conviction in its investment strategy and the undeniable opportunities in the Asian healthcare market. Quadria Capital's largest existing backers include prominent North American and European sovereign wealth funds, asset managers, and strategic corporates. The Fund also secured new commitments from globally recognized institutional investors. Most notably, there was strong backing from leading institutions across the GCC, including Saudi Arabia, the UAE, and Bahrain. The fundraise further attracted interest from India, with fresh capital from major banks, insurance companies, and family offices. Additionally, the Fund received robust re-up commitments from impact investors – underscoring Quadria's continued dedication to scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia. Positioned for Structural Growth in Asia's $5 Trillion Healthcare Market 'With Asia expected to drive 40% of global healthcare growth by 20301, Fund III positions Quadria to lead a new era of private capital-driven healthcare transformation across the region,' Abrar Mir added. 'Asia's healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single-specialty hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing, which includes APIs and CDMOs. This sector will see growth because of higher healthcare consumption, cost-efficiency initiatives, and deepening technology integration. We are entering a golden decade of healthcare transformation. Our investment philosophy centers on forging deep partnerships with India's healthcare visionaries as the 'partner of choice', providing strategic guidance and operational support to help them scale their businesses and achieve market leadership,' said Dr Amit Varma, Co-Founder and Managing Partner, Quadria Capital. India As A Core Market for Healthcare Innovation and Investment Quadria Capital's investment thesis is especially relevant in India, where healthcare transformation is both a national imperative and a private capital opportunity. India is emerging as a strategic manufacturing hub as global pharmaceutical and MedTech supply chains shift towards the country Per capita healthcare spend in India stands at just $74, significantly below regional peers like Thailand ($364) and Malaysia ($487), with nearly 50% of all healthcare costs paid out-of-pocket The new fundraise can fuel Indian healthcare innovation by strategically deploying capital in high-growth sectors like specialised care and pharma manufacturing, with a focus on building scalable, affordable solutions for over a billion people. Fund III will build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes, and further scaling impact through targeted co-investments from Limited Partners (LPs). Already nearly 40% deployed – including closed and signed investments – the fund has invested in Aragen Life Sciences (a global CRDMO serving over 400 pharma clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's leading eye care chain). Two new investments in Southeast Asia are expected soon. Fund III builds on Quadria Capital's track record of successful exits from Funds I and II, underscoring the strength of its investment strategy, operational expertise and ability to distribute capital back to investors. About Quadria: Founded in 2012, Quadria Capital is Asia's premier healthcare investor managing over US$4 billion in assets across 27 investments in South and Southeast Asia including India, Vietnam, Indonesia, Malaysia and Singapore. Quadria Capital aims to create significant and sustainable shareholder value by partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors. For more information, please visit 1https:// View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
5 days ago
- Business
- Yahoo
Quadria Capital Closes Oversubscribed US$1 Billion Fund III to Advance Healthcare Transformation Across Asia
Fund close exceeds initial target despite a challenging fundraising environment, reflecting strong investor confidence in India and Southeast Asia healthcare Existing investors increased commitment amount by an average of 80% New capital raised from blue-chip global institutions, alongside a significant rise in Asian investor participation SINGAPORE, May 27, 2025--(BUSINESS WIRE)--Quadria Capital, Asia's premier healthcare-focused private equity firm, today announced the final close of its Fund III with US$1.07 billion in total commitments, significantly exceeding its original $800 million target. The oversubscribed fundraise comprises over US$954 million in primary commitments and US$114 million in committed co-investment capital. An additional US$300 million co-investment capacity is anticipated over the course of the investment phase, bringing total committed capital to approximately US$1.3 billion upon full deployment. This latest fundraise is around 60% larger than the firm's previous $600m fund raised in 2020, cementing Quadria's position as the largest dedicated healthcare private equity fund in South and Southeast Asia. "Fund III's close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission," said Abrar Mir, Co-Founder and Managing Partner, Quadria Capital. "It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand." Global Institutional Backing Across Continents At a time when global capital is cautious, Quadria's ability to consistently attract top-tier global investors underscores the strong conviction in its investment strategy and the undeniable opportunities in the Asian healthcare market. Quadria Capital's largest existing backers include prominent North American and European sovereign wealth funds, asset managers, and strategic corporates. The Fund also secured new commitments from globally recognized institutional investors. Most notably, there was strong backing from leading institutions across the GCC, including Saudi Arabia, the UAE, and Bahrain. The fundraise further attracted interest from India, with fresh capital from major banks, insurance companies, and family offices. Additionally, the Fund received robust re-up commitments from impact investors - underscoring Quadria's continued dedication to scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia. Positioned for Structural Growth in Asia's $5 Trillion Healthcare Market "With Asia expected to drive 40% of global healthcare growth by 20301, Fund III positions Quadria to lead a new era of private capital-driven healthcare transformation across the region," Abrar Mir added. "Asia's healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single-specialty hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing, which includes APIs and CDMOs. This sector will see growth because of higher healthcare consumption, cost-efficiency initiatives, and deepening technology integration. We are entering a golden decade of healthcare transformation," said Dr Amit Varma, Co-Founder and Managing Partner, Quadria Capital. Fund III will build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes, and further scaling impact through targeted co-investments from Limited Partners (LPs). Already nearly 40% deployed - including closed and signed investments - the fund has invested in Aragen Life Sciences (a global CRDMO serving over 400 pharma clients), NephroPlus (Asia's largest dialysis chain), and Maxivision (India's leading eye care chain). Two new investments in Southeast Asia are expected soon. Fund III builds on Quadria Capital's track record of successful exits from Funds I and II, underscoring the strength of its investment strategy, operational expertise and ability to distribute capital back to investors. About Quadria: Founded in 2012, Quadria Capital is Asia's premier healthcare investor managing over US$4 billion in assets across 27 investments in South and Southeast Asia including India, Vietnam, Indonesia, Malaysia and Singapore. Quadria Capital aims to create significant and sustainable shareholder value by partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors. For more information, please visit 1 View source version on Contacts Media Contact: Yvette
